SCHRODINGER INC (SDGR)

US80810D1037 - Common Stock

19.44  +0.14 (+0.73%)

After market: 19.44 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SDGR. SDGR was compared to 37 industry peers in the Health Care Technology industry. SDGR has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, SDGR is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SDGR has reported negative net income.
SDGR had a negative operating cash flow in the past year.
In the past 5 years SDGR reported 4 times negative net income.
SDGR had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of SDGR (-26.53%) is comparable to the rest of the industry.
The Return On Equity of SDGR (-39.51%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -26.53%
ROE -39.51%
ROIC N/A
ROA(3y)-9.96%
ROA(5y)-9.8%
ROE(3y)-14.64%
ROE(5y)-14.58%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of SDGR (64.91%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SDGR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SDGR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.4%
GM growth 5Y0.16%

More info and screens

8

2. Health

2.1 Basic Checks

SDGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
SDGR has more shares outstanding than it did 1 year ago.
SDGR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SDGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.65 indicates that SDGR is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.65, SDGR is doing good in the industry, outperforming 66.67% of the companies in the same industry.
There is no outstanding debt for SDGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.65
ROIC/WACCN/A
WACC9.27%

2.3 Liquidity

SDGR has a Current Ratio of 4.11. This indicates that SDGR is financially healthy and has no problem in meeting its short term obligations.
SDGR has a Current ratio of 4.11. This is amongst the best in the industry. SDGR outperforms 86.11% of its industry peers.
SDGR has a Quick Ratio of 4.11. This indicates that SDGR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.11, SDGR belongs to the top of the industry, outperforming 86.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 4.11

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SDGR have decreased strongly by -526.32% in the last year.
Looking at the last year, SDGR shows a decrease in Revenue. The Revenue has decreased by -3.03% in the last year.
The Revenue has been growing by 26.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-526.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
Revenue 1Y (TTM)-3.03%
Revenue growth 3Y26.08%
Revenue growth 5Y26.61%
Sales Q2Q%-17.1%

3.2 Future

SDGR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.11% yearly.
Based on estimates for the next years, SDGR will show a quite strong growth in Revenue. The Revenue will grow by 15.36% on average per year.
EPS Next Y-547.12%
EPS Next 2Y-157.95%
EPS Next 3Y-82.68%
EPS Next 5Y64.11%
Revenue Next Year-8.38%
Revenue Next 2Y7.66%
Revenue Next 3Y11.54%
Revenue Next 5Y15.36%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SDGR. In the last year negative earnings were reported.
Also next year SDGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as SDGR's earnings are expected to decrease with -82.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-157.95%
EPS Next 3Y-82.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SDGR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCHRODINGER INC

NASDAQ:SDGR (12/20/2024, 8:00:01 PM)

After market: 19.44 0 (0%)

19.44

+0.14 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners95.58%
Inst Owner Change0.99%
Ins Owners2.43%
Ins Owner Change0.44%
Market Cap1.42B
Analysts81.18
Price Target32.64 (67.9%)
Short Float %14.73%
Short Ratio12.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.67%
Min EPS beat(2)14.46%
Max EPS beat(2)14.87%
EPS beat(4)3
Avg EPS beat(4)5.82%
Min EPS beat(4)-6.54%
Max EPS beat(4)14.87%
EPS beat(8)6
Avg EPS beat(8)22.21%
EPS beat(12)8
Avg EPS beat(12)15.42%
EPS beat(16)9
Avg EPS beat(16)7.6%
Revenue beat(2)1
Avg Revenue beat(2)1.61%
Min Revenue beat(2)-14.72%
Max Revenue beat(2)17.94%
Revenue beat(4)1
Avg Revenue beat(4)-4.82%
Min Revenue beat(4)-14.72%
Max Revenue beat(4)17.94%
Revenue beat(8)3
Avg Revenue beat(8)-0.33%
Revenue beat(12)7
Avg Revenue beat(12)6.85%
Revenue beat(16)8
Avg Revenue beat(16)4.12%
PT rev (1m)1.73%
PT rev (3m)-3.83%
EPS NQ rev (1m)-11.9%
EPS NQ rev (3m)-11.9%
EPS NY rev (1m)2.61%
EPS NY rev (3m)2.65%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-4.26%
Revenue NY rev (1m)-3.42%
Revenue NY rev (3m)-3.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.33
P/FCF N/A
P/OCF N/A
P/B 3.15
P/tB 3.19
EV/EBITDA N/A
EPS(TTM)-2.43
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS2.65
BVpS6.17
TBVpS6.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.53%
ROE -39.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.91%
FCFM N/A
ROA(3y)-9.96%
ROA(5y)-9.8%
ROE(3y)-14.64%
ROE(5y)-14.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.4%
GM growth 5Y0.16%
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.23%
Cap/Sales 4.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 4.11
Altman-Z 2.65
F-Score4
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)225.85%
Cap/Depr(5y)159.5%
Cap/Sales(3y)5.27%
Cap/Sales(5y)4.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-526.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
EPS Next Y-547.12%
EPS Next 2Y-157.95%
EPS Next 3Y-82.68%
EPS Next 5Y64.11%
Revenue 1Y (TTM)-3.03%
Revenue growth 3Y26.08%
Revenue growth 5Y26.61%
Sales Q2Q%-17.1%
Revenue Next Year-8.38%
Revenue Next 2Y7.66%
Revenue Next 3Y11.54%
Revenue Next 5Y15.36%
EBIT growth 1Y-23.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.22%
EBIT Next 3Y3.7%
EBIT Next 5YN/A
FCF growth 1Y-41.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.83%
OCF growth 3YN/A
OCF growth 5YN/A